ABSTRACT: Colorectal cancer (CRC) is a genetic disease, due to progressive accumulation of mutations in oncogenes and tumor suppressor genes. Large scale genomic sequencing projects revealed >100 mutations in any individual CRC. Many of these mutations are likely passenger mutations, and fewer are driver mutations. Of these, activating mutations in RAS proteins are essential for cancer initiation, progression, and/or resistance to therapy. There has been significant interest in developing drugs targeting mutated cancer gene products or downstream signaling pathways. Due to the number of mutations involved and inherent redundancy in intracellular signaling, drugs targeting one mutation or pathway have been either ineffective or led to rapid resistance. We have devised a strategy whereby multiple cancer pathways may be simultaneously targeted for drug discovery. For proof-of-concept, we targeted the oncogenic KRAS and HIF pathways, since oncogenic KRAS has been shown to be required for cancer initiation and progression, and HIF-1α and HIF-2α are induced by the majority of mutated oncogenes and tumor suppressor genes in CRC. We have generated isogenic cell lines defective in either oncogenic KRAS or both HIF-1α and HIF-2α and subjected them to multiplex genomic, siRNA, and highthroughput small molecule screening. We have identified potential drug targets and compounds for preclinical and clinical development. Screening of our marine natural product library led to the rediscovery of the microtubule agent dolastatin 10 and the class I histone deacetylase (HDAC) inhibitor largazole to inhibit oncogenic KRAS and HIF pathways. Largazole was further validated as an antiangiogenic agent in a HIF-dependent manner in human cells and in vivo in zebrafish using a genetic model with activated HIF. Our general strategy, coupling functional genomics with drug susceptibility or chemical-genetic interaction screens, enables the identification of potential drug targets and candidates with requisite selectivity. Molecules prioritized in this manner can easily be validated in suitable zebrafish models due to the genetic tractability of the system. Our multidimensional platform with cellular and organismal components can be extended to larger scale multiplex screens that include other mutations and pathways. O ncogenic RAS mutations including HRAS, KRAS, and NRAS are found in approximately 30% of all human tumors, with KRAS being the most prevalent.
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■ RESULTS

Comparative Gene Expression
We next examined whether the gene set involved in the canonical HIF pathway is regulated by oncogenic KRAS. Using IPA, we filtered for gene perturbations affecting the canonical HIF pathway. Genes in the HIF pathway involve growth factor receptors, signaling protein cascades including the Ras/Raf/ MAPK and PI3K/AKT pathways, the HIF transcription factors and regulatory proteins (i.e., VHL, proteasome), and downstream target genes (glucose transporters, glycolysis enzymes, and angiogenic factors). Activation of growth factor receptors and signaling proteins would lead to the induction of HIF-1α and HIF-2α, and the consequent transactivation of target genes ( Figure 1c and Supporting Information Table S1 ). As shown in Supporting Information Figures S1a and b The isogenic lines were seeded at densities which yielded equivalent cellular confluency at the time of detection. We subjected the cells to the siRNA library (20 nM) and assessed differential cytotoxicity 96 h later (48 h to allow knockdown and an additional 48 h to allow a downstream effect). If an siRNA inhibited oncogenic KRAS or HIF-1α/HIF-2α pathway, it should inhibit the parental cells and not the knockout cells. A correlation in siRNA-induced cytotoxicity was seen between parental HCT116 and HCT116
HIF-1α−/−HIF-2α−/− ( Figure 2a ) and between parental HCT116 and HCT116
WT KRAS (Figure 2b ) cells. Hits were identified as those with a viability ratio of the parental HCT116 to one of the knockout cells (parental:ko) < 0.6, p < 0.05 across replicates, and a minimum of two siRNAs causing differential toxicity (Supporting Information Table S2 ). High-confidence hits (176 genes, highlighted in red) were identified as those with three or four siRNAs causing differential cytotoxicity (Figures 2a and b) . Using Venn diagram ( Figure 2c ) and heatmap analyses (Figure 2d ), all hits were grouped into those that affect the oncogenic KRAS pathway only, the HIF-1α/ HIF-2α pathway only, or both oncogenic KRAS and HIF-1α/ HIF-2α pathways. A total of 153 hits with statistically significant differential toxicity were shared between isogenic knockout lines ( Figure 2c ).
The top canonical pathways, biological processes, and networks of all hits were generated through the use of QIAGEN's Ingenuity iReport. A significant amount of overlap was seen between the top canonical pathways of siRNAs inhibiting KRAS and HIF-1α/HIF-2α pathways. The top 10 canonical pathways included protein ubiquitination, nucleotide excision repair (NER) (Supporting Information Figure S3 ), systemic lupus erythematosus signaling, Huntington's disease signaling, assembly of RNA polymerase II complex, estrogen receptor signaling, androgen signaling, and glucocorticoid receptor signaling pathways were all shared among hits ( Figure 2e and Supporting Information Table S3a ,b). While most of the pathways contain proteins which have been shown to have interactions with either HIF-1α, HIF-2α, or KRAS, some of these pathways have not been strongly linked to HIF and KRAS pathways. The assembly of RNA polymerase II complex contains no proteins that have been shown to have direct interactions with HIF-1α, HIF-2α, or KRAS. Only one interaction (HIF-1α with RAD23B) 9 has been previously reported in the nucleotide excision repair pathway. Within the protein ubiquitination pathway, only two interactions with HIF-1α (STUB1, PSMA4), 10, 11 two interactions with HIF-2α (PSMB1, STUB1), 10, 12 and one interaction with KRAS (PSMA30) 13 have been reported. With 31 focus molecules per data set, "RNA Post-Transcriptional Modification, Cellular Assembly and Organization" was the most significant network, with oncogenic KRAS and HIF networks also containing "Infectious Disease" and "Cell Cycle" functionalities, respectively (Supporting Information Table S4 ). Further discussion and description of IPA outcomes including common upstream regulators (Supporting Information Figure S4 ) can be found in the Supporting Information Results and Methods sections. A Gene Ontology (GO) analysis revealed that the RNA modification processes are largely associated with RNA splicing via the spliceosome and transesterification reactions.
14 Interestingly, when evaluating high confidence hits, major biological processes involved antigen and multiorganismal (symbiotic and viral) processes. High-confidence hits were evaluated to determine top biological processes and top molecular functions shared between active siRNAs. GO analysis of high confidence hits revealed that functions centered around cell cycle and growth signaling were among the top functions with KRAS/HIFassociated toxicity (Figure 2f ). Since we identified the protein ubiquitination pathway, we then evaluated a proteasome inhibitor, bortezomib, in our isogenic screening system where it exhibited differential effects on cell viability (Figure 2g ). Bortezomib also reduced levels of HIF-driven transcripts, including VEGFA (Figure 2h ), consistent with previous reports that it is a HIF-1 inhibitor, 15 while validating our screen. A global network was generated using IPA in which top networks with a minimum of five shared molecules were connected (Figure 2i ). Top diseases and biofunctions within this network include RNA post-transcriptional modification, cellular assembly and organization, infectious disease, cell cycle, molecular transport, and RNA trafficking. Major nodes identified in these hits include the NFκB complex and Akt, suggesting that these pathways are involved with HIF/KRAS associated toxicity. It has been previously shown that NFκB is involved in the expression of HIF-1α 16 and microtubule depolymerizational activation of HIF-1α occurs through a NFκB dependent mechanism. 17 Additionally, studies have demonstrated the role of HIF-1α in the binding of the NFκB complex to DNA. 18 Furthermore, KRAS has been shown to increase activation of the NFκB complex and enhances the protein DNA binding activity of NFκB complexes consisting of p50 and p65 subunits, further confirming this crosstalk. 19 The PI3K-Akt pathway, which promotes survival and growth, has been shown to associate with both HIF-1α and KRAS. Akt increases activation of HIF-1α protein. 20 Interference of HIF-1α was shown to decrease activation of Akt via PLGF protein. 21 Similarly, the presence of dominant negative Akt proteins in MC3T3-E1 cells was shown to decrease the activation of HIF-1α during ultrasound. 22 Several studies have also highlighted the involvement of KRAS in the activation and phosphorylation of Akt proteins, further supporting crosstalk between the HIF/KRAS and the PI3K/ Akt pathways. 23−28 Additional top overlapping networks not connected to the top global network include those with functionality in RNA post-transcriptional modification, cell cycle, cellular assembly, organization, gene expression, DNA replication, recombination and repair, and cancer (Supporting Information Table S5 ). The top diseases and biofunctions of active siRNAs were also assessed independently of shared network molecules to evaluate the global impact of the hits on a biological system based on activation z-score (Supporting Information Table S5 ). Interestingly, many of our hits demonstrate some overlap with the functionalities of synthetic lethals targeting KRAS. Although a significant amount of overlap is rarely seen between synthetic lethal screens, certain genes including POLR2B, PSMA2, POLR2G, PSMA, CDC6, E2F1, and PSMD14 have been previously reported 29 (Supporting Information Table S6 ).
Small Molecule Screen for Inhibitors of Oncogenic KRAS and HIF Pathways. For proof-of-concept studies, we , proscillaridin (100 nM), peruvoside (100 nM), parbendazole (2 μM), and verteporfin (1 μM). (g) Proscillaridin (100 nM) and peruvoside (100 nM) abrogated HIF-1α protein levels completely, while partially suppressing HIF-1β. Verteporfin, parbendazole, and deoxysappanone B-DMEA had no effect on HIF-1α and HIF-1β protein levels.
We selected 261 compounds for further testing, which included ones showing differential cytotoxicity and those that were toxic to both cell types at 10 μM concentration (the latter to incorporate potential false negatives which could demonstrate differential toxicity at lower concentrations; Figure 3b ). Several compounds showed up as hits from multiple libraries, serving as an internal validation including podophyllotoxin, niclosamide, anthothecol, camptothecin and its analogue 10-hydroxycamptothecin, and methotrexate and its analogue aminopterin. Using dose− response analysis, we identified 55 compounds (Supporting Information Figure S5a −e and Table S7 ) which showed differential cytotoxicity with dose titration to lower concentrations (Figure 3b ). These compounds exhibited overlap in their mechanisms of action, including calcium channel regulation, DNA metabolism, cardiac glycoside functionality, folic acid biosynthesis, microtubule stability, p53 regulation, and protein synthesis regulation (Figure 3c ). We generated a network in an effort to investigate overlap between the small molecule screen with the siRNA screen. Figure 3d demonstrates direct links between our screens, with functional (cell cycle checkpoints, DNA replication) and canonical pathway (protein ubiquitination pathway, BRCA1 DNA damage response, and hereditary breast cancer signaling) overlap also indicated. Interestingly, an increased incidence of colon cancer has been reported in BRCA1 mutation carriers, which is also part of hereditary breast cancer signaling. 30 Many molecules have shown previous associations with HIF, providing confidence to our screen. Others have not yet been previously associated with HIF and KRAS (highlighted in light blue), which warrant further investigation.
We further validated five compounds (verteporfin, proscillaridin, peruvoside, parbendazole, and deoxysappanone B 7,3′-dimethyl ether acetate) as they showed promising differential cytotoxicity for parental HCT116 cells over HCT116 HIF-1α−/−HIF-2α−/− cells in terms of IC 50 shift and/or efficacy and represented structural and biochemical diversity (Figure 3e) . Verteporfin, parbendazole, and deoxysappanone B 7,3′-dimethyl ether acetate have not been previously identified as HIF inhibitors. All five compounds caused significant downregulation of HIF target genes (Figure 3f ). Proscillaridin and peruvoside completely suppressed HIF-1α protein expression, producing "pharmacological HIF-1α knockouts" (Figure 3g ), while others did not greatly affect protein levels, suggesting different mechanisms of HIF inhibition. We also measured differential cytotoxicity of parental HCT116, which has oncogenic KRAS mutation, versus the isogenic oncogenic KRAS knockout cell line (HCT116 WT KRAS ), and found that these five compounds are more effective in the presence of oncogenic KRAS (Figure 3e) .
Characterization of Marine Natural Products as HIF Inhibitors in Vitro and in Vivo. We next screened our library of marine natural products and identified dolastatin 10 31 as an agent that preferentially acts on HIF-containing cells (Figure 4a ). Dolastatin 10 demonstrated a strong decrease in potency in both HCT116 HIF-1α−/−HIF-2α−/− and HCT116 WT KRAS cells (IC 50 shift from 0.48 to 65.2 and 24.2 μM, respectively), as well as a decrease in total efficacy (74% and 83%, respectively). We also found the class I HDAC inhibitor largazole 32, 33 to demonstrate significant differential cytotoxicity for parental HCT116 over HCT116 HIF-1α−/−HIF-2α−/− and HCT116 WT KRAS cells (Figure 4a ). The potency of largazole is reduced by 3-fold in HCT116
HIF-1α−/−HIF-2α−/− cells (IC 50 shift from 6.41 to 18.1 μM), concomitant with reduced efficacy (70%). For cells lacking oncogenic KRAS, the IC 50 s are comparable with parental cells; however the efficacy is reduced to 67%. The differential cytotoxicity of largazole for parental HCT116 over HCT116 HIF-1α−/−HIF-2α−/− cells indicates that the antiproliferative activity of largazole is partially HIF-dependent and that this pathway represents a major mechanism of action. HIF target genes are potently downregulated by largazole (Figure 4b ) in HIF-containing HCT116 cells. HIF-1α is also reduced at the transcriptional (Figure 4c ) and protein level (Figure 4d ). Largazole showed inhibitory activity in the HCT116 colony formation assay at 10 nM (Figure 4e ) and reduced cytotoxicity against a HIF-independent cell line, RKO, 34 compared with HCT116 and LoVo (Figure 4f) . Largazole was also effective in an in vitro angiogenesis assay using human umbilical vein endothelial cells (HUVECs), decreasing the number of branch points of the tube network (Figure 4g ) without affecting cell viability, while downregulating several proangiogenic factors (VEGFA, FGF2) and upregulating antiangiogenic factors (THS2; Figure 4h ).
We next tested for the Hdac1 inhibitory function of largazole in vivo, through administration of 500 nM to zebrafish larvae from 19 hpf. By 48 hpf, these larvae displayed phenotypes reminiscent of the zebrafish hdac1 mutant, colgate, 35, 36 including blood pooling and pigment pattern defects (Figures 5a and b) . We tested if largazole-mediated inhibition of Hdac1 would also have an antiangiogenic effect in zebrafish. To mimic pathogenic vascular defects, we exploited the excess vascularization seen in vhl hu2117 mutants. The Vhl protein is a negative regulator of Hif-1α, such that these mutants have excessive vascularization of the trunk and head, including a vascular plexus in the tail (Figures 5c and d) , a process mediated by VEGFA. 
■ DISCUSSION
Our data demonstrated that isogenic knockouts of cancer genes can be used in multiplex screens to define targets and drugs affecting complex cancer pathways. Although isogenic knockouts have been used to find drugs affecting a single cancer pathway, 38, 39 we show that multiple cancer pathways can be targeted at once by multiplex screens. As proof-of-concept, parental HCT116, HCT116
HIF-1α−/−HIF-2α−/− , and HCT116 WT KRAS cells were subjected to multiplex high-throughput screening (HTS) with an siRNA library targeting the druggable genome and with small molecule libraries to identify agents that show toxicity only in cells that express the oncogenic KRAS and HIF transcription factors.
From our siRNA screen, we identified eight canonical pathways to be associated with oncogenic KRAS and HIF pathways: protein ubiquitination, nucleotide excision repair, systemic lupus erythematosus signaling, Huntington's disease signaling, assembly of RNA polymerase II complex, estrogen receptor signaling, androgen signaling, and glucocorticoid receptor signaling. Our siRNA data are consistent with prior reports that HIF-α mediates transcription of target genes by directly associating with transcriptional cofactors and RNAPII 40 and that proteasomal inhibitors inactivate HIF transcriptional activity. 41 Our data suggest that targeting these canonical pathways should be further developed for treating cancers with oncogenic KRAS mutation.
We have discovered small molecules that inhibit oncogenic KRAS and HIF pathways. Proscillaridin and peruvoside are cardiac glycosides and have previously been reported to exhibit cytotoxic activity in colorectal cancer cells 42 and inhibit HIF-1α protein synthesis through inhibition of mitochondrial respiration. 43 We further showed that they also inhibit the oncogenic KRAS pathway. We identified three novel oncogenic KRAS/HIF inhibitors: parbendazole, a deoxysappanone derivative, and verteporfin. Parbendazole is an inhibitor of microtubule assembly, and antimicrotubule agents have been previously shown to inhibit HIF transcriptional activity by suppressing HIF-α translation and expression. 44 Our results suggest that parbendazole might inhibit HIF transcriptional activity independent of its antimicrotubule activity, as HIF protein expression was not affected in our cell-based system. Deoxysappanone is a component of green tea and has been shown to possess antidiabetic properties by activating mitochondria. 45 Verteporfin is a benzoporphyrin used as a photosensitizer in photodynamic therapy to treat macular degeneration. 46 The mechanism of inhibition of HIF target gene expression by these compounds cannot be explained by effect on HIF protein expression. Further experiments are needed to elucidate how these agents regulate HIF transcriptional activity.
When we screened a subset of our natural products that we isolated from marine cyanobacteria, we identified the microtubule-depolymerizing agent dolastatin 10, 32 consistent with the differential cytotoxicity of the microtubule-stabilizing agent paclitaxel in our initial screen. We also identified the class I HDAC inhibitor largazole as a novel inhibitor of the oncogenic KRAS and HIF pathways. 33, 34 Largazole inhibited the expression of HIF-1α and HIF target genes (incl. VEGFA) and induced the antiangiogenic factor, THS2, which presumably contributes to its antiangiogenic and antitumor activity. The mechanism of largazole inhibition of HIF expression is at the transcriptional and protein level through modulation of gene expression and probably also decrease of HIF stability, suggested to be perturbed by HDAC inhibition. Isoforms HDAC1 and HDAC3 are reported to associate with HIF-1α and modulate the expression of HIF-1α target genes and thus regulate angiogenesis, 47, 48 whereas isoform HDAC2 modulates transcriptional activity through its interaction with the tumor suppression gene p53. 49 It is likely that largazole also inhibits HIF transcriptional activity through its binding to HDACs; however, further experiments are needed.
Zebrafish provide a powerful model system that is extensively exploited for mechanistic studies and also shows promise for drug screening. 50 The relevance of the HIF inhibitory and antiangiogenic activity of largazole in vitro was demonstrated in vivo. Largazole mimicked the Hdac1 knockout phenotype in zebrafish consistent with in vitro enzymatic and cellular data that largazole is a HDAC inhibitor. Importantly, largazole was able to inhibit HIF-induced vascularization in a zebrafish mutant with activated HIF pathway, indicating that our cellular screens have predictive power for the identification of in-vivo-active HIF inhibitors by sufficiently mimicking in vivo conditions. Our results further emphasize that zebrafish systems are well suited as an intermediate platform to predict in vivo bioavailability of HIF inhibitors. Largazole has shown in vivo activity in numerous studies with cancer and noncancer applications. 33 As a proof of concept, we demonstrated that multiplex screens of complex cancer pathways, oncogenic KRAS and HIF, can be used to find targets and drugs common to both pathways. Our high-throughput siRNA screen data show that there are targets unique to each pathway (oncogenic KRAS or HIF). Drugs may be tailored to specific circumstances depending on the presence of certain pathway(s). Last, the general methodology presented here can be applied to other conditions and mutations through interrogating the corresponding pathways in vitro and in vivo ( Figure 6 ). Coupling functional genomics with drug susceptibility or chemical-genetic interaction screens enables the identification of potential drug targets and small molecules as new tool compounds or starting points for drug discovery. Molecules prioritized in this manner can easily be validated in suitable zebrafish models due to the genetic tractability of the system and the predictive power of activity in higher organisms. 
